Seminars in Oncology
Volume 33, Supplement 6 , Pages 26-32, April 2006

The Role of Gemcitabine in First-Line Treatment of Advanced Ovarian Carcinoma

  • Tate Thigpen

      Affiliations

    • Prof Thigpen has served as a consultant and invited speaker for Eli Lilly & Co.
    • Corresponding Author InformationAddress reprint requests to Prof Tate Thigpen, University of Mississippi School of Medicine, 2500 N State St, Jackson, MS 39216.

Division of Oncology, University of Mississippi School of Medicine, Jackson, MS.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00122-9

doi:10.1053/j.seminoncol.2006.03.015

Seminars in Oncology
Volume 33, Supplement 6 , Pages 26-32, April 2006

Article Tools